U.S. Food and Drug Administration (FDA) has granted Fast Track status to BriaCell’s lead candidate, Bria-IMT™, for the treatment of metastatic breast cancer. Fast Track improves the speed and frequency of communication with FDA, potentially leading to earlier drug approval and access by patients. BriaCell is currently enrolling and dosing advanced breast cancer patients in …
Based on clinical data with Bria-IMT™, BriaCell has developed Bria-OTS™, an off-the-shelf (i.e. pre-manufactured) personalized immunotherapy. Bria-OTS™ will be used to treat patients with advanced breast cancer, providing patients with readily available personalized treatment. PHILADELPHIA and VANCOUVER, British Columbia, April 12, 2022 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or …
Bria-OTS™ would build on BriaCell’s existing clinical trial data with Bria-IMT™, treating each patient with the optimized pre-manufactured Bria-OTS™ formulation based on HLA-type. BriaCell and National Cancer Institute collaborating on Bria-OTS™, BriaCell’s off-the-shelf personalized immunotherapy, as a treatment for cancer. BriaCell to present Bria-OTS™ approach at the American Association for Cancer Research (AACR) Annual Meeting …
PHILADELPHIA and VANCOUVER, British Columbia, Feb. 23, 2022 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”) , a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, is pleased to announce that it has appointed leading immunologist, Alexander Kharazi, M.D., Ph.D., to its Scientific Advisory Board. …
PHILADELPHIA and VANCOUVER, British Columbia, Feb. 16, 2022 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”) , a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, announces the appointment of Giuseppe Del Priore, MD, MPH, as the Company’s Chief Medical Officer (CMO), effective today. Dr. …
BriaCell selected to present at the American Association for Cancer Research (AACR) Annual Meeting 2022 Corporate buyback program continues; 1,031,672 shares and 200,740 warrants repurchased since program commencement Insiders intend to acquire up to approximately 10% of BriaCell’s common shares, or 1.59 million shares PHILADELPHIA and VANCOUVER, British Columbia, Feb. 10, 2022 (GLOBE NEWSWIRE) — …
NEW YORK and VANCOUVER, British Columbia, Jan. 19, 2022 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”) , is pleased to announce that all resolutions proposed to shareholders at the Annual and Special Meeting of Shareholders (the “Meeting” ) held virtually via teleconference on January 18, 2022 were …
BERKELEY, Calif. and VANCOUVER, British Columbia, May 11, 2021— BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, today announced that Dr. William V. Williams, President & CEO of BriaCell, is scheduled to participate in the following virtual conferences: • Benzinga …
BERKELEY, Calif. and VANCOUVER, British Columbia, April 15, 2021— BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, announces that it has recently expanded its investor and media outreach platform in order to enhance communication with investors and increase investor awareness …
BERKELEY, Calif. and VANCOUVER, British Columbia, April 12, 2021 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, today announced that it has completed the sale of an additional 882,352 shares at the public offering price of US$4.24 …